4-methyl-N-[(3-methyl-4-isoxazolyl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine | 675619-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-N-[(3-methyl-4-isoxazolyl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine
• 英文别名: 4-methyl-N-[(3-methyl-1,2-oxazol-4-yl)methyl]-6-(4-methylsulfonylphenyl)pyridin-2-amine
• CAS: 675619-79-1
• 化学式: C₁₈H₁₉N₃O₃S
• 分子量: 357.433
• InChiKey: PKHKNWQIBCZJMC-UHFFFAOYSA-N

物化性质

• 沸点：
  600.0±50.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] COX-2 INHIBITING PYRIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIDINE INHIBITEURS DE LA COX-2
  申请人：GLAXO GROUP LTD

  公开号：WO2004024691A1

  公开（公告）日：2004-03-25

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.

  式(I)的化合物或其药学上可接受的盐是COX-2的有效和选择性抑制剂，并可用于治疗各种疾病和疾病的疼痛、发热和炎症。
• Cox-2 Inhibiting pyridine derivatives
  申请人：Beswick Paul

  公开号：US20060040988A1

  公开（公告）日：2006-02-23

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.

  公式（I）化合物或其药学上可接受的盐是COX-2的有效和选择性抑制剂，并可用于治疗各种疾病和情况的疼痛，发热和炎症。
• Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
  申请人：Hagan James

  公开号：US20070142411A1

  公开（公告）日：2007-06-21

  The invention concerns the use of compounds of formula (I), (II) and (III) which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts and solates thereof, for the treatment of schizophrenic disorders. Schizophrenic disorders of the invention are to be intended schizophrenia, delusional disorders, affective disorders, autism or tic disorders, schizophreniform disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders. Moreover, the invention is concerned with the use of a pyrimidine derivative known as COX-2 inhibitor in combination with a neuroleptic drug for the treatment of schizophrenic disorders such as those defined above.

  本发明涉及使用式（I）、（II）和（III）化合物及其药学上可接受的盐和溶剂，作为COX-2（环氧合酶-2）抑制剂，用于治疗精神分裂症。本发明的精神分裂症指精神分裂症、妄想性障碍、情感障碍、自闭症或抽动障碍、类精神分裂症、特别是慢性精神分裂症和分裂情感性精神病、暂时急性精神病性障碍。此外，本发明涉及使用一种称为COX-2抑制剂的嘧啶衍生物与神经精神药物结合治疗上述定义的精神分裂症。
• Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders
  申请人：Hagan James

  公开号：US20070270428A1

  公开（公告）日：2007-11-22

  The invention concerns the use of compounds of formula (I), (II) and (III): which are COX-2 (cyclooxygenase-2) inhibitors, and pharmaceutically acceptable salts or solvates thereof, for the treatment of depressive disorders in combination with an effective amount of a second component which is a selective serotonin reuptake inhibitor.

  本发明涉及使用式（I），（II）和（III）的化合物：这些化合物是COX-2（环氧合酶-2）抑制剂，以及其药学上可接受的盐或溶剂，与第二成分的有效量结合使用，该第二成分是选择性血清素再摄取抑制剂，用于治疗抑郁症。
• COX-2 INHIBITING PYRIDINE DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1546107A1

  公开（公告）日：2005-06-29